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Background: Cetuximab (Cx)+ radiation therapy (RT) is well-tolerated and has improved
survival in patients (pts) with locoregionally advanced head and neck squamous cell car-
cinomas (LA-HNSCC). However, its efficacy when compared to HD-DDP+RT has been
questioned. At our institution, low-dose weekly carboplatin is added to Cx+RT for patients
unsuitable for HD-DDP.
Methods: We reviewed records of 16 patients with LA-HNSCC treated with definitive
Cx+ carboplatin+RT at the University of Miami from 2007 to 2011. Median follow-up was
24 months (range: 1–69 months).
Results: Median age: 71.5 years (range: 57–90 years); 15 male, 1 female. ECOG PS 0=15,
1=1. TNM staging was: T 1=1, T 2=5, T 3=8, T 4=2; N stage: N0=8, N1=5, N2a=2,
N2b=1. All patients received weekly carboplatin (AUC 1.5–2), Cx given conventionally and
daily conventionally fractionated RT. Median total weeks of concurrent systemic therapy=7
(range: 3–8 weeks). RT was delivered to a median total dose of 70 Gy (range 30–74 Gy). Of
the 15 evaluable patients, there were: 12 CR, 2 PR, and 1 PD. There were three local in-
field failures, two regional failures, and three distant failures. At last follow-up, 8/15 patients
remained with NED. Three-year locoregional recurrence was 28.3% (95% CI: 7.7–53.9%).
Mean percentage of weight loss was 14% (range: 6–26%).Two patients required systemic
therapy dose reduction. Three patients experienced a treatment delay and three did not
finish RT as planned including a patient who received only 30 Gy due to death secondary
to MI during treatment.
Conclusion: In this small retrospective series, carboplatin/Cx/RT was well-tolerated and
efficacious in patients unsuitable for HD-DDP having LA-HNSCC. Acute toxicities were
similar to Cx+RT, likely due to the non-overlapping toxicity profiles of the two systemic
agents. We hypothesize that the addition of a well-tolerated cytotoxic chemotherapy agent
may improve the therapeutic ratio of Cx+RT in patients who are poor candidates for more
aggressive therapies and warrants evaluation in a prospective manner.
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INTRODUCTION
In the past two decades, there have been important advances
in the management of locoregionally advanced head and neck
squamous cell carcinomas (LA-HNSCC). The efficacy of radia-
tion therapy (RT) with concurrent chemotherapy has altered the
treatment approach of these patients from aggressive surgery to
one that allows for organ preservation, thereby decreasing cos-
metic and functional impairments while maintaining comparable
long-term control rates to strategies involving definitive surgical
resection. Based upon the results of several phase III random-
ized controlled trials as well as a large meta-analysis, concurrent
chemoradiation therapy has become the standard of care approach
for patients seeking non-surgical therapy (1–6). For this group of
patients, a radiation dose to gross disease of approximately 70 Gy
is commonly used with concurrent high-dose cisplatin-based
chemotherapy (CRT). While overall survival (OS) is superior with
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such regimens compared to treatment with radiation alone, the
addition of chemotherapy adds to the mucosal, gastrointestinal,
and metabolic toxicity of treatment.
Unfortunately, a sizeable proportion of LA-HNSCC patients,
particularly those who are elderly, those with compromised per-
formance status, or those with significant medical comorbid-
ity, may not be appropriate candidates for full-dose concurrent
cisplatin-based chemoradiation therapy. For these patients, alter-
native choices of less toxic systemic therapy in combination with
RT are attractive therapeutic options. The epidermal growth fac-
tor receptor (EGFR, ErbB-1) has been found to be expressed in
virtually all head and neck squamous cell carcinomas. Binding of
growth factor ligands to EGFR leads to its constitutive activation,
which results in changes in gene expression, anti-apoptotic activ-
ity, and increased cell proliferation (7). Cetuximab (Cx) (Ertibux®,
Bristol–Myers Squibb) is a chimeric monoclonal antibody that
binds to the ligand-binding domain of EGFR and inhibits receptor
activation, thereby preventing the aforementioned events that lead
to tumor progression. It is also postulated to have radiosensitizing
effects (8).
Results from a randomized phase III trial by Bonner et al. have
shown that the addition of Cx to RT alone leads to improvements
in all clinically relevant outcomes, including OS (9). However,
combination cetuximab/RT has not been compared to CRT using
conventional cytotoxic agents in a randomized setting, and recent
retrospective data suggest inferior outcomes with Cx/RT when
compared with CRT (10, 11). Despite this, Cx/RT remains the
treatment regimen of choice at many institutions for patients
not suitable for CRT. At our institution, the perceived under-
whelming results with Cx/RT have led us to add an additional
low-dose systemic radiosensitizing chemotherapy agent with a
non-overlapping side effect profile (carboplatin) to Cx/RT on a
case-by-case basis for patients who are not suitable to receive CRT
in an effort to improve outcomes without adding excessive toxic-
ity. Carboplatin was chosen because it has been utilized by some
investigators as the backbone of concurrent systemic therapy with
RT in multiple published studies (12, 13). We now report the toxic-
ity and clinical efficacy of combination carboplatin/cetuximab/RT
(CCRT) and provide the first report in the literature using this reg-
imen, in order to determine if it is suitable for further prospective
evaluation.
MATERIALS AND METHODS
This retrospective review was approved by the University of Miami
Institutional Review Board. We reviewed the medical records
of patients treated with concurrent CCRT at the University of
Miami Sylvester Comprehensive Cancer Center between 1/2007
and 12/2011. In total, 16 patients were identified who presented
with newly diagnosed, biopsy-proven non-metastatic squamous
cell carcinomas of the oropharynx, larynx, or hypopharynx who
then completed a course of organ-preserving therapy with this reg-
imen. Patients were offered this treatment regimen primarily due
to advanced age and/or frailty, baseline abnormalities in organ
function such as chronic renal insufficiency or hearing loss that
would preclude the safe use of cisplatin, or poor functional reserve
and/or social support that would render completing a course of
CRT excessively difficult.
All patients were assigned a performance status using the ECOG
criteria (14). Staging was performed clinically as per the AJCC
2010 guidelines (version 7.0) (15). Toxicities were graded using
the National Cancer Institute Common Terminology Criteria for
Adverse Events v4.0 (NCI-CTCAE 4.0) (16). Patients were encour-
aged, but were not required, to undergo prophylactic feeding tube
placement.
Systemic therapy was delivered using a loading dose of Cx at
400 mg/m2 1 week prior to initiating RT. At the start of RT and
thereafter, Cx was given weekly at 250 mg/m2 along with weekly
carboplatin at an AUC of 1.5–2 mg/ml/min. RT was delivered
using megavoltage linear accelerators to deliver conventionally
fractionated RT at 2 Gy/fx to a total dose of approximately 70 Gy to
gross disease in 33–35 fractions delivered once-daily on weekdays.
Generally, patients were treated using intensity modulated radia-
tion therapy (IMRT) using dose-painting techniques. Following
therapy, patients were observed with routine clinical examina-
tion combined with radiographic imaging for disease surveillance.
Imaging typically included a contrasted neck CT scan at 6 weeks
from the completion of CRT and a PET–CT scan at 12 weeks from
the completion of CRT. For persistent disease and/or disease pro-
gression, surgical salvage was offered if patients were deemed to
be appropriate candidates. Study endpoints related primarily to
toxicity and efficacy. Specific toxicity endpoints were Grade 3–5
mucositis, rash, dermatitis, dysphagia, and xerostomia.
The follow-up duration was calculated starting on the date of
diagnosis. The date of progression was selected as the date of first
event including locoregional recurrence (LRR), distant metastasis,
or death. LRR was defined as recurrence at the primary site or
in the neck after a disease-free interval. Patients who were alive
without evidence of progression were censored at the date of last
contact. OS was defined as the time from diagnosis to death from
any cause with surviving patients censored at date of last con-
tact. Progression-free survival (PFS) and OS were estimated by the
Kaplan–Meier method.
RESULTS
PATIENT AND TUMOR CHARACTERISTICS
Patient and tumor characteristics of the cohort are summarized
in Table 1. We identified a total of 16 patients who were treated
with a course of definitive concurrent CCRT. Median age at diag-
nosis was 71.5 years (range: 57–70 years); 15/16 were male. At
baseline, all patients had an ECOG performance status of 0 or
1. The race/ethnicity of the patients studied was as follows: 3
White/Non-Hispanic, 11 White/Hispanic, and 2 Black. Medical
comorbidities were common in the cohort and their incidence is
summarized in Table 2. All patients selected to receive this regimen
had at least one chronic medical condition. The medical oncolo-
gists involved assessed the candidates globally in terms of aggregate
medical comorbidities and did not restrict the regimen specifically
to patients with a decreased baseline performance status,but rather
to patients felt to be frail and therefore have inadequate functional
reserve to withstand more aggressive therapy. A gastrostomy tube
was placed in 9/16 patients, with no patient requiring any other
form of enteral nutrition.
Of note, two patients received induction cytotoxic therapy
prior to starting the regimen of CCRT. One patient received
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Table 1 | Patient and disease characteristics.
Variable N %
Total patients 16
AGEAT DIAGNOSIS
Median (min, max) 71.5 (57, 90)
SEX
Male 15 94
Female 1 1
RACE/ETHNICITY
White/non-Hispanic 3 19
White/Hispanic 11 69
Black 2 12
DISEASE SITE
Tonsil 4 25
Base of tongue 5 31
Supraglottic larynx 2 12
Larynx 4 25
Hypopharynx 1 6
TSTAGE
T 1 1 6
T 2 5 31
T 3 8 50
T 4 1 6
T x 1 6
NSTAGE
N0 8 50
N1 5 31
N2a 2 12
N2b 1 6
N2c 0 0
N3 0 0
GROUP STAGE
I 0 0
II 1 6
III 10 63
IVA 4 25
IVB 1 6
IVC 0 0
three cycles of Cx/docetaxel, and the other received a single cycle
of paclitaxel/cisplatin/5-FU but did not tolerate it well and the
induction chemotherapy was discontinued. These patients were
included as the backbone of their therapy was the regimen in
question (CCRT), and the addition of induction therapy would
only potentially increase toxicities; therefore their inclusion would
be unlikely to skew results in a positive direction. After a loading
dose of Cx 400 mg/m2 1 week prior to RT, on day 1 of RT, Cx
was delivered at 250 mg/m2 along with carboplatin at an AUC of
1.5 mg/ml/min to 13 patients and at an AUC of 2 mg/ml/min to
3 patients. Only one patient, who received treatment at an AUC
of 2 mg/ml/min, required a dose reduction of carboplatin. Two
patients required a dose reduction of Cx, primarily due to skin tox-
icity. The median number of concurrent systemic therapy cycles
delivered was seven (range: 3–7 weekly cycles), with one patient
Table 2 | Incidence of medical comorbidities.
Variable N
Total patients 16
COMORBIDITIES
Hypertension 12
COPD/asthma 6
Coronary artery disease 4
Diabetes mellitus 4
Hypothyroidism 2
Hx of malignancy 2
HIV 1
Chronic kidney disease 1
NUMBER CONCURRENT ILLNESSES
One 1
Two 5
Three 4
Four 3
Five 1
Nine 1
Ten 1
Median number of comorbidities 3
dying of a cardiac event 3 weeks into concurrent therapy. It was
this patient who received only three cycles of chemotherapy and
was treated to only 30 Gy.
Radiation therapy was given daily at 2.0–2.12 Gy prescribed to
gross disease to a median total dose of 70 Gy (range: 30–74 Gy).
Fifteen of sixteen patients were treated using IMRT, and 15/16
also received RT to the neck nodal regions bilaterally. The sin-
gle patient who did not receive elective neck RT was treated for
a newly diagnosed second primary head and neck squamous cell
carcinoma nearly 20 years after being treated with RT, so field sizes
were minimized accordingly.
TOXICITY
Acute toxicities were graded as per the NCI-CTCAE 4.0 and are
summarized in Table 3. Overall, the regimen was well-tolerated.
The maximum percent weight loss at any point during or after
therapy for patients receiving this regimen had a median of 14%.
Most patients who underwent PEG tube placement had their
access removed at 6–12 weeks following the end of therapy. One
patient died with a feeding tube in place, and another had a PEG
tube in place at last follow-up. There was no incidence of PEG tube
placement after the end of CCRT due to severe acute toxicities of
therapy. There was one death during treatment at approximately
3 weeks due to a cardiac event; this was felt to be unrelated to treat-
ment and the patient was excluded from the outcomes analysis but
not from the toxicity analysis.
CLINICAL RESPONSE/OUTCOMES
The median follow-up for the cohort was 24 months (range: 1–
69 months). Of the 15 evaluable patients, 12 responded completely
to CCRT with no residual clinical or radiographic evidence of dis-
ease, 2 responded partially, and 1 patient experienced disease pro-
gression. At the last follow-up, 8/15 patients remained disease-free.
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Table 3 | Acute toxicities.
Grade 0 Grade 1 Grade 2 Grade 3 Grade 4
Leukopenia 6 9 0 0 1
Anemia 9 5 1 1 0
Thrombocytopenia 15 1 0 0 0
Acneiform rash 9 1 6 0 0
Radiation dermatitis 1 1 8 6 0
Mucositis 1 0 8 7 0
Dysphagia/odynophagia 1 0 9 5 1
Xerostomia 5 3 8 0 0
FIGURE 1 | Progression-free (A) and overall survival (B) of patient cohort.
Overall, seven patients experienced a failure: three local failures,
two regional failures (one of which occurred in a patient who
previously experienced a local failure), and three distant failures.
All local/regional failures occurred within the radiation fields. Of
the distant failures, two patients metastasized to the lungs, while
another developed liver metastases. All 16 patients, including the
1 who died of a cardiac event 3 weeks into treatment of non-
treatment-related causes, are included in the statistical analysis,
with death from unrelated cause treated as a competing risk. The
3-year cumulative incidence of LRR was 28.3% (95% CI: 7.7–
53.9%) and 19.4% for distant metastases (95% CI: 4.3–42.6%).
Three-year PFS was 39.7% (95% CI: 15.6–63.2%), while 3-year
OS was 71.4% (95% CI: 39.8–88.4%), which are summarized in
Figure 1.
DISCUSSION
The mainstay of therapy for patients with newly diagnosed
LA-HNSCC has become RT with concurrent cisplatin-based
chemotherapy. While most protocols incorporating cisplatin and
RT use large bolus doses of chemotherapy (100 mg/m2 q3
weeks× 2–3 cycles), other regimens have used lower doses (20–
40 mg/m2) weekly in an effort to reduce toxicities. However,
neither of these regimens is feasible for a substantial number of
patients with a decreased performance status or multiple medical
comorbidities. While the combination of Cx/RT is often employed
in this patient population and is superior to RT alone, its efficacy
when compared to CRT regimens using cisplatin has been ques-
tioned (10, 11). In a recent retrospective review by Koutcher
et al. from Memorial Sloan Kettering, treatment outcomes were
compared between cohorts of patients receiving cetuximab/RT
vs. those who received cisplatin/RT. The 2-year failure-free sur-
vival clearly favored the group receiving cisplatin (87.4 vs. 44.5%,
p< 0.0001), as did the 2-year OS rates (92.8 vs. 66.6%,p= 0.0003)
(10). Similar results were presented by a group from Washington
University, with disease-specific survival (85 vs. 29%, p= 0.0012)
and OS (79 vs. 20%, p= 0041) favoring cisplatin/RT with propen-
sity score adjustments made for differences in baseline characteris-
tics (11). While any retrospective analysis is subject to an inherent
selection bias, these data suggest the superiority of cisplatin-based
CRT regimens over Cx/RT, although this has yet to be studied in a
prospective manner. Here, we present a novel treatment regimen
which, to our knowledge, has not been previously reported in the
literature. By adding a well-tolerated low-dose cytotoxic agent to
a backbone of Cx/RT, we sought to improve treatment outcomes
without adding excessive toxicity. Our results indicate that the
addition of low-dose carboplatin to Cx/RT appears to produce
favorable response rates while remaining a tolerable treatment
regimen for this patient population.
In order to better understand the feasibility of this regimen, we
compared the results in the current study to those reported in the
prospective trial by Bonner et al., which established Cx/RT as a
standard treatment regimen for patients with newly diagnosed
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Table 4 | Comparison of toxicities.
Toxicity (Grade 3–5) Current study Bonner et al. (9)
n=16 n=208
Mucositis (%) 44 56
Acneiform rash (%) 0 (Highest Grade 2) 17
Radiation dermatitis (%) 38 23
Dysphagia (%) 38 26
Xerostomia (%) 0 (Highest Grade 2) 5
Table 5 | Comparison of outcomes.
Outcome (3-year estimates) Current study Bonner et al. (9)
Carboplatin+ Cetuximab+RT
cetuximab+RT n=208
n=16
Overall response (%) 93 74
Locoregional control (%) 71.7 47
Progression-free survival (%) 39.7 42
Overall survival (%) 71.4 55
HNSCC of the oropharynx, larynx, or hypopharynx. We first
compared rates of Grade 3–5 toxicities, which overall revealed
similar incidences between those patients treated on our study as
compared to historical controls from the Bonner trial (Table 4).
The lack of significantly increased toxicity with the addition of
a systemic chemotherapy agent points towards the tolerability of
low-dose carboplatin as well as the non-overlapping side effect
profiles of the two systemic agents which were combined (9).
We also compared response rates between the current study
and historical controls. Fourteen of 15 evaluable patients in our
trial had either a partial or complete response, corresponding to
a crude response rate of 93%. This compares favorably to the
74% CR/PR rate noted in the Bonner study. When comparing
long-term control, patients in the current analysis had a 3-year
locoregional control (LRC) of 71.7% (95% CI: 46.1–92.3%), vs.
47% in the Bonner trial. Three-year survival was 71.4% (95%
CI: 39.8–88.4%) in our study vs. 55% in the Bonner study (9).
These results are summarized in Table 5. Of note, while the dis-
tribution of primary site of disease is similar between our series
and the Bonner study, our study did have a greater proportion of
patients with stage III disease (63 vs. 25%), which could explain
our favorable outcomes. Our results are also certainly limited by
our small sample size, but they do suggest that CCRT is an effective
and well-tolerated treatment approach that may warrant further
prospective evaluation.
It is important to keep in perspective the patient population in
whom there may be a benefit of adding low-dose carboplatin to
Cx/RT. In our observational study, the regimen was only offered
to patients who were not felt to be candidates for cisplatin. For
those patients who are more fit, the addition of Cx to a backbone
of cisplatin/RT for LAHNC was evaluated in a phase III trial by the
RTOG (0522) (17). At interim analysis, there was no improvement
in PFS or OS with the addition of Cx to cisplatin/RT, while there
was an increase in acute toxicities. Although long-term results of
this RTOG study are not yet available, it would be unlikely that
these results will differ significantly given the natural history of
head and neck cancers. Our study, by contrast, focused on patients
who were too frail to receive full-dose of cisplatin and for whom
RT plus Cx was the current standard approach. It is for this rea-
son that we do not feel that the negative results from RTOG 0522
are relevant to this discussion. We acknowledge that combining
cisplatin-based CRT with Cx may not result in an increase in
therapeutic efficacy compared to cisplatin-based CRT alone. Our
hypothesis is that adding carboplatin to Cx increases efficacy while
not increasing toxicity significantly beyond that seen with Cx/RT.
In the studies discussed above including our cohort, the largest
group of patients presented with primary tumors of the orophar-
ynx. Over the past decade, we have become aware of changes in
the biology and etiology of oropharyngeal squamous cell carci-
nomas, which are now more often related to exposure to human
papillomavirus (HPV), as opposed to the traditional chemical car-
cinogens of tobacco and alcohol (18). In RTOG 0522, 73% of
patients with oropharyngeal tumors had HPV-positive carcino-
mas, using p16 as a surrogate immunohistochemical marker for
HPV positivity (17). These patients have higher rates of tumor
response and long-term disease control compared to p16 negative
patients, and p16 is now accepted as an independent prognostic
indicator in this population (19). In the current series, all four
patients with known p16+ disease remain free of disease at last
follow-up. Our lack of p16 staining data for all included patients
is certainly a limitation of our analysis, as it would be notewor-
thy to evaluate our results, or perhaps those of a planned phase II
prospective trial of CCRT, in the context of HPV status.
Whether treatment can be de-intensified in HPV+ patients
with oropharyngeal SCC is the focus of a phase III RTOG trial,
which is currently underway (RTOG 1016), in which patients
with p16+ oropharyngeal SCC are being randomized to Cx/RT
vs. cisplatin/RT (18). If the results of this trial indicate non-
inferiority of Cx/RT in this setting, then our CCRT regimen may
not be needed for p16+ oropharynx patients. We would then focus
our evaluation on the p16− population. However, if the RTOG
demonstrates Cx/RT to be inferior to CRT for the p16+ popula-
tion, then our regimen may still warrant evaluation in LA-HNSCC
patients regardless of p16 status.
CONCLUSION
For LAHNC patients who are not suitable candidates to receive
cisplatin-based CRT, treatment options remain limited. By adding
a low-dose of an alternative cytotoxic chemotherapy agent (carbo-
platin) to RT and Cx, we have identified a new treatment regimen
that appears to be well-tolerated and may improve upon the thera-
peutic ratio of Cx/RT by increasing efficacy without adding signif-
icant toxicity. Although our results are limited by our small sample
size and retrospective analysis, they are hypothesis-generating and
suggest that this regimen should be evaluated in a prospective
manner. A phase II trial is in development at our institution.
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